Pacira BioSciences vs Ultragenyx Pharmaceutical
PCRX and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PCRX and RARE compare
Pacira BioSciences and Ultragenyx Pharmaceutical are about the same size, with market caps of $1.5B and $1.6B.
Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (17.5% versus 5.7% for Pacira BioSciences).
Pacira BioSciences keeps more of each dollar of sales as profit, with a net margin of 2.0% compared with −81.7% at Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 6 for Pacira BioSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PCRX | RARE |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $1.6B |
| Share price | $36.48 | $16.70 |
| Change, 1 year | 53.4% | −49.5% |
| Change, 5 years | −29.3% | −78.2% |
| Beta (5Y) | 0.12 | 2.12 |
| Employees | 829 | 1,371 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 104× | – |
| P/S | 1.9× (better) | 2.3× |
| P/B | 2.2× | – |
| EV/EBITDA | 14.9× | – |
| P/FCF | 8.1× | – |
| FCF yield | 12.3% (better) | −29.7% |
| Fair value | $28.47 | – |
| Margin of safety | −28.1% | – |
| Growth | ||
| Revenue growth (TTM) | 5.7% | 17.5% (better) |
| Revenue growth, 5Y average | 11.1% | 19.9% (better) |
| EPS growth, 5Y average | −45.5% | – |
| Profitability | ||
| Gross margin | 79.2% | – |
| Operating margin | 2.7% (better) | −73.6% |
| Net margin | 2.0% (better) | −81.7% |
| FCF margin | 24.1% (better) | −68.2% |
| Return on equity | 2.0% | – |
| Return on invested capital | 3.0% | – |
| Financial health | ||
| Debt / equity | 0.54 | – |
| Net debt / EBITDA | 1.07 | – |
| Interest coverage | 1.3× | – |
| Current ratio | 5.04 (better) | 1.73 |
| Altman Z-score | 2.44 (better) | −5.26 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 10.2% | – |
| Shareholder yield | 10.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 110% | 108% |
| Held by insiders | 6.1% | 4.0% |
| Insider net buying, 12 months | −$2.4M (better) | −$3.8M |
| Short interest, % of float | 8.9% | 25.0% |
Go deeper
- PCRX stock overview
- PCRX income statement
- PCRX valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.